Investor Overview

Stock Information
Loading data...
Press Releases
Jun 28, 2022

Agreement Significantly Expands Access to Phexxi® for Millions of Women Seeking an FDA-Approved, Hormone-Free, On-Demand Option to Prevent Pregnancy Long-term Contract Adds to Growing List of...

Jun 16, 2022

Throughout 24,289 Acts of Intercourse, 101 Pregnancies were Reported with Typical Use of Phexxi in AMPOWER Post Hoc Analysis SAN DIEGO, June 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc.,...

Jun 2, 2022

Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that the U.S. Food and Drug Administration (FDA) has formally extended the shelf life of Phexxi® (lactic acid, citric acid,...

May 20, 2022

Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock, 12,835,000...

May 19, 2022

Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu of common...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com.  

The Company is evaluating Phexxi for two potential new indications: the prevention of urogenital chlamydia and gonorrhea in women. Top-line results are expected from its confirmatory Phase 3 clinical trial, EVOGUARD, in the second half of 2022. Positive outcomes could support submission to the FDA for these potential new indications in the first quarter of 2023, with an anticipated PDUFA date in the second half of 2023 due to the expedited review afforded by the Fast Track designations granted for these indications.

The addressable U.S. market opportunity for these current and investigational indications is estimated at $3.6 - $4.5 billion in aggregate.  

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. Discussions are underway with potential licensees for commercialization of Phexxi in multiple international markets.

Featured Event
Monday, June 13, 2022 - Thursday, June 16, 2022

View All

Latest Financial Results

Q1 2022, Ended March 31, 2022

Earnings Release
Earnings Call
10-Q Filing
XBRL